Dechra Pharmaceuticals’ share price hits record peaks! Is it a top UK share to buy?

The Dechra Pharmaceuticals share price has just risen to new all-time highs. Here’s why I think it’s a good buy today.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Dechra Pharmaceuticals (LSE: DPH) share price has been steadily improving in health during the past year. The business — which manufactures medicines for both companion animals and livestock — has risen 52% in value since early June 2020. This UK healthcare share hit fresh record peaks of £43.20 on Tuesday too, after it released fresh trading news.

Dechra’s share price settled lower and it closed Tuesday’s session at £42.52. Still, this represented a healthy 3% rise on the day. And I think the FTSE 250 company will continue to climb in value.

Sales tipped to beat estimates

In its latest sunny update, Dechra announced that trading for the full year to June 30 is likely to beat market expectations.

Should you invest £1,000 in M&G right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if M&G made the list?

See the 6 stocks

In February it advised that it had experienced a “strong performance” for the first seven months of financial 2021. And yesterday Dechra said it has “continued to benefit from strong market fundamentals as well as lower underlying selling, general and administration costs” following the Covid-19 outbreak.

Pre-Brexit stockpiles of its medicines are set to finish unwinding and coronavirus restrictions are on course to keep easing. So, Dechra “is increasingly confident that this strong performance will continue for the rest of this financial year.”

The UK share said full-year revenue is likely to exceed current consensus predictions, therefore. Trading is likely to be more evenly distributed than previously guided between the first and second halves of the financial year too.

Profits surge drives Dechra’s share price

Dechra Pharmaceuticals’ share price has exploded in recent years. A strong record of annual earnings growth has seen the FTSE 250 share rise 310% in value over the past half a decade. And City analysts are expecting profits at the business to continue rising at a swift pace.

The number crunchers reckon that earnings will rise 11% in the financial year to June 2021. And they’re forecasting a 7% bottom-line advance in fiscal 2022.

It’s worth bearing in mind that Dechra trades on an elevated forward price-to-earnings (P/E) ratio of 39 times. This increases the chances of a share price correction should news flow around the company begin to disappoint. This could include problems with medicines R&D, a not uncommon problem in the pharma industry that can result in large extra costs and lost revenues.

Why I’d buy this UK share

That being said, I still think Dechra is a good buy, even at today’s high price. This is because the veterinary medicines market is expected to keep on growing rapidly. Analysts at Grand View Research expect it to expand at a compound annual growth rate of 7.4% through to 2028. They reckon this will be driven by “rising R&D and procedural advancements, pet adoption rate, and increasing consumption of meats and mandatory vaccination.”

And I think Dechra, with its broad stable of products and healthy product pipeline, is well placed to exploit this booming industry.

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Investing Articles

Rolls-Royce shares are up almost 500% in 2 years! Will the bubble burst?

Over the past two years, Rolls-Royce shares have gone parabolic, returning 470% since March 2023. But can the UK’s top…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
US Stock

3 actionable takeaways from Warren Buffett’s latest letter for stock market investors

Jon Smith reviews some of his favourite points from Warren Buffett's latest letter to investors, including the large cash pile…

Read more »

Investing Articles

I asked ChatGPT how I should invest £1,000 in UK stocks. Here’s what it said!

Charlie Carman turns to artificial intelligence for ideas on how to invest a four-figure sum in UK stocks, with some…

Read more »

Close up view of Electric Car charging and field background
Investing Articles

£10,000 invested in NIO stock 1 year ago is now worth…

NIO stock was a favourite among growth-oriented investors in 2020 and 2021. But it didn’t deliver. Dr James Fox spies…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

Down 37% from May, does Glencore’s near-£3 share price look cheap to me?

Glencore’s share price has tumbled from its one-year traded high, which suggests there may be good value in it. I…

Read more »

Dividend Shares

How much would an investor need in dividend shares to make £1,000 a month?

Jon Smith talks through both the strategy and the numbers behind the investment aim of using dividend shares to make…

Read more »

A row of satellite radars
Investing Articles

Defence spending is on the rise and this UK growth stock could be set to cash in

With the UK ready to increase its defence spending, Stephen Wright thinks the stock likely to benefit the most isn’t…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£11,000 in savings? Here’s how investors could use that to target an annual passive income of £12,892 over time!

Money put into high-dividend-paying shares with the returns used to buy more of them can generate potentially life-changing passive income.

Read more »